Drug intelligence / Profile preview

qingfei sanjie granule

Development stage: Unknown
Lead developer: Guangdong Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Qingfei Sanjie granule is a Traditional Chinese Medicine (TCM) formulation developed by the Guangdong Provincial Hospital of Traditional Chinese Medicine for the treatment of pulmonary nodules. Specifically indicated for patients with nodules classified as Lung-RADS 2–3 and a TCM syndrome of Qi deficiency with dampness-heat stagnation, the granule aims to stabilize or reduce nodule size by resolving phlegm and clearing heat. It is currently being investigated in a randomized, placebo-controlled phase 0 clinical trial to evaluate its safety and preliminary efficacy in an adult population.

Other names: Qingfei Sanjie Formula

Beyond the preview

Go deeper on qingfei sanjie granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on qingfei sanjie granule.

Explore the full profile